Mired in low ex­pec­ta­tions, No­vo braces for up­com­ing Ca­griSe­ma head-to-head tri­al

No­vo Nordisk’s late-stage weight loss da­ta showed Ca­griSe­ma per­formed be­low an­a­lysts’ ex­pec­ta­tions.

It’s the sec­ond late-stage clin­i­cal let­down for the can­di­date, and the find­ings mean …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER